Table 1 Patient characteristics at vedolizumab start
Total n (%) | 12 (100) |
|---|---|
Male n (%) | 5 (42) |
Type of disease n (%) | |
Crohn’s disease | 7 (58) |
Ulcerative colitis | 4 (34) |
Unclassified inflammatory bowel disease | 1 (8) |
Age yr, median (range) | 15 (8–17) |
Disease duration yr, median (range) | 2 (1–9) |
Previous biologicals n (%) | |
Infliximab | 12 (100) |
Adalimumab | 11 (92) |
Golimumab | 1 (8) |
Reasons for discontinuation | |
Infliximab n (%) | |
Primary non-responder | 3 (25) |
Loss of response | 7 (58) |
Anaphylactic reaction | 2 (17) |
Adalimumab n (%) | |
Primary non-responder | 2 (18) |
Loss of response | 7 (64) |
Local allergic reaction | 2 (18) |
Golimumab n (%) | |
Loss of respone | 1 (100) |